Summary
PSTX Chart
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Poseida Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Guillaume Binnendijk Cigogne Management SA | 120,000 | $1.15M | $1.15M | - | - |
Poseida Therapeutics, Inc. (PSTX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Poseida Therapeutics, Inc. Profile
| - Industry | - Sector | Mr. Mark J. Gergen J.D. CEO | NASDAQ (NGS) Exchange | 73730P108 CUSIP |
| US Country | 330 Employees | - Last Dividend | - Last Split | 10 Jul 2020 IPO Date |
Overview
Poseida Therapeutics, Inc., represents a clinical-stage biopharmaceutical entity specialized in the development of novel therapeutics aimed at fulfilling the unmet needs of patients across various medical disciplines. With its foundation laid in 2014 and based in San Diego, California, the company has steadily positioned itself at the forefront of biomedical research and development. Through its consistent efforts and strategic partnerships, including collaborations with renowned entities like F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Poseida Therapeutics has dedicated itself to harnessing the power of genetic engineering and cell therapy. This pursuit is driven by the overarching goal of addressing and potentially overcoming complex health challenges, particularly within the realms of heme malignancies, solid tumors, prostate cancer, hemophilia A, ornithine transcarbamylase deficiency, and phenylketonuria.
Products and Services
- P-BCMA-ALLO1: Currently in Phase I trial, this development candidate aims at treating patients with relapsed or refractory multiple myeloma. A hallmark of Poseida Therapeutics' innovation, this therapy represents the cutting-edge in allogeneic CAR-T cell technologies targeting high unmet medical needs within heme malignancies.
- P-CD19CD20-ALLO1: In Phase I clinical trial, this product candidate focuses on the treatment of B cell malignancies and various autoimmune diseases, exemplifying the company's commitment to expanding its portfolio into broader areas of unmet medical need within hematology.
- P-BCMACD19-ALLO1: As a preclinical development candidate, this allogeneic, off-the-shelf CAR-T product signifies Poseida's ongoing efforts to tailor cellular therapies for multiple myeloma treatment, promising a new approach to cancer care.
- P-CD70-ALLO1: Under preclinical development, aimed at addressing hematological indications. This therapeutic candidate further underscores the company’s pursuit of novel targets and pathways to combat cancer more effectively.
- P-MUC1C-ALLO1: Entering Phase I trial, this product endeavours to treat a spectrum of solid tumors, including but not limited to breast, colorectal, lung, ovarian, pancreatic, and renal cancers, providing a glimmer of hope for patients battling these formidable diseases.
- P-PSMA-ALLO1 & P-PSMA-101: With P-PSMA-ALLO1 in preclinical development and P-PSMA-101 under Phase 1 clinical trial, both of these autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates represent innovative approaches to targeting metastatic castrate-resistant prostate cancer (mCRPC), a testament to the company’s dedication to advancing prostate cancer therapy.
- P-FVIII-101: A clinical-stage liver-directed gene therapy targeting in vivo treatment of hemophilia A, showcasing Poseida Therapeutics' venture into gene therapies aimed at curing genetic disorders through cutting-edge genetic editing and delivery technologies.
- P-OTC-101: Another clinical-stage liver-directed gene therapy, this time focusing on the in vivo treatment of ornithine transcarbamylase deficiency, illustrates the company’s commitment to addressing rare metabolic disorders through innovative therapeutic approaches.
- P-PAH-101: Embarking on the clinical stage as a liver-directed gene therapy for the in vivo treatment of phenylketonuria, this product underscores Poseida Therapeutics’ investment in expanding its genetic therapeutic solutions to encompass a wider range of genetic and metabolic disorders.
